论文部分内容阅读
探讨 Ｃ－ ｅｒｂ Ｂ－ ２ 和 Ｐ２１ 癌基因蛋白表达在乳腺癌发生发展过程和早期诊断中的意义． 用免疫组化方法检测乳腺良性病变、癌前病变和癌３ 组 Ｃ－ ｅｒｂ Ｂ－ ２ ， Ｐ２１ 癌基因蛋白的表达． 结果： （１） Ｃ－ ｅｒｂ Ｂ－ ２蛋白在３ 组病变中的阳性表达率分别为３２３ ％ （１／３１） ， ６１１１ （１１／１８） ， ８９６５ ％ （２６／２９） ， 癌前病变组表达低于癌组（ Ｐ＜ ００５） ， 良性病变组明显低于癌前组 （ Ｐ＜ ００１） ， 癌组表达最高． （２） Ｐ２１ 蛋白在３ 组病变中的阳性表达率分别为３５４８ ％ （１１／３１） ， ９４４４ ％ （１７／１８） ， ９６５５ ％ （２８／２９） ， 癌前病变与癌组表达无显著差异， 良性病变组表达明显低于癌前组 （ Ｐ＜ ００１） ， 癌组表达最高． （３） 上述两种癌基因蛋白在乳腺病变从良性→癌前→癌变的发生发展过程中， 表达程度逐渐增高． （４） 两种癌基因蛋白在３ 组病变中同时表达率分别为３２２ ％ （１／３１） ， ５０ ％ （９／１８） 和８６２ ％ （２５／２９） ． 结论： Ｃ－ ｅｒｂ Ｂ－ ２ ， ｒａｓ Ｐ２１ 基因蛋白过度表达与癌变有关． 两者的同步检测对乳癌的早期?
2. To explore the significance of C - erb B - 2 and P21 oncogene protein expression in the development and early diagnosis of breast cancer. Immunohistochemistry was used to detect the expression of C-erb B-2 and P21 oncogene proteins in benign lesions, precancerous lesions, and carcinomas. Results: (1) The positive expression rates of C-erb B-2 protein in 3 groups were 323% (1/31), 6111 (11/18), 8965% (26/29). In the precancerous lesions, the expression was lower in the precancerous lesions than in the cancerous lesions (P < 0. 05). The benign lesions were significantly lower than in the precancerous lesions (P <0. 01). (2) The positive expression rates of P21 protein in 3 groups were 35.8% (11/31), 94.4% (17/18), and 96.5% (28/29) respectively. There was no significant difference in the expression of the cancer group. The benign lesions were significantly lower than the precancerous lesions (P < 0 01). The highest expression was observed in the carcinoma. (3) The above two oncoproteins gradually increase in the development of breast lesions from benign→precancerous→cancer. (4) The simultaneous expression rates of the two oncoproteins in 3 groups were 322% (1/31), 50% (9/18) and 862% (25/29). Conclusion: Overexpression of C-erb B-2 and ras P21 protein is associated with carcinogenesis. The simultaneous detection of both of the early stages of breast cancer?